Creo Medical Group PLC · LSE:CREO

Creo Medical — Investor Presentation (2022)

41 slides from Creo Medical's investor presentation, 2022

  1. Slide 1: Bringing Advanced Energy to Endoscopy

    Bringing Advanced Energy to Endoscopy Anything is Possible with the Right Approach

  2. Slide 2: Disclaimer

    Disclaimer IMPORTANT NOTICE This presentation comprises the written materials/slides (“presentation”) concerning Creo Medical Group PLC (the “Company”) and technologies and/or products developed or under development by the Company. By reviewing this presentation you agree to be bound by the followin

  3. Slide 3: The Evolution of Advanced Energy

    The Evolution of Advanced Energy 1. Coherent Market Insights, Laparoscopic Devices Market Analysis – Jan 2020. 2. Boston Scientific investor presentation, 2015. 3. Conmed investor presentation, August 2016 4. Intuitive 2021 Earnings Estimate presentation and Creo market analysis. 5 JAMA Network Open

  4. Slide 4: Creo Medical Overview

    $3-4bn GI Endoscopic Instrument Addressable Creo Medical Overview Market 1,2 with minimal competition 2016 / 2017 ▪ IPO ▪ Regulatory clearances and first • Creo Medical develops and commercialises early clinical use a suite of electrosurgical medical devices, each enabled by its CROMA platform, powe

  5. Slide 5: Commercial & Operational Highlights

    Commercial & Operational Highlights “ Speedboat and the entire Creo Growth in revenue driven by Creo’s core technology platform represent one of the underpinned by stable revenue from consumables business most innovative contributions to endoscopic energy delivery in the past several • Progress in r

  6. Slide 6: CONFIDENTIAL © Creo Medical 2022

    6 CONFIDENTIAL © Creo Medical 2022

  7. Slide 7: Creo – A Global Company

    Creo – A Global Company Follow us on Twitter & LinkedIn @CreoEndoscopy and @CreoMedical Around the World in 80 days ORSI Academy, Belgium Baylor Simulation Lab, USA Endo 2022, Japan Chulalongkorn Hospital, Thailand Hospital Universitario, Spain EMIS Research Facility, France East Kent Hospital, UK S

  8. Slide 8: Patients

    Patients 8 Confidential © Creo Medical 2022. CONFIDENTIAL © Creo Medical 2022

  9. Slide 9: Launching our Endotherapy Accessories in the US

    Launching our Endotherapy Accessories in the US Areas to target • Resection, Dissection, Myotomy Commercial Impact • Strong margins • Excellent link to POEMs case • 4 clips to close incision • ~$400 per case • Global distribution possible following taking manufacturing responsibility • Plan is to ev

  10. Slide 10: MicroBlate Fine Treats First Pancreatic Tumours

    MicroBlate™ Fine Treats First Pancreatic Tumours Carlos Robles Medranda - Global KOL and trainer MicroBlate Fine Microwave Ablation (MWA) of NET Tumour EUS Guided MWA CT Scan 2 Months Post Ablation • Recognised international KOL provide fast validation and product iteration • 6cm tumour treated in D

  11. Slide 11: MicroBlate Fine – Case Report

    MicroBlate Fine – Case Report Dr Sundeep Lakhtakia AIG Hyderabad, India Patient History: 64Y / Male patient has a Neuroendocrine Tumour (NET) in the pancreas, measuring 25mm x 15mm size​ Ablation Time: 120 s (2 min) applied twice due to irregular shape of the mass​ Follow-Up: CT in 1-2 months​ 11 CO

  12. Slide 12: Chepstow Site

    Chepstow Site • Acquired site in H2-21 for £4m, mortgage completed for £2.25 plus grant of £800k from Welsh Government • Landlord was selling hence need to acquire and retain production at current site – Risk Mitigation • Mortgage cost equal to annual rent • Have capacity and relevant plan for next

  13. Slide 13: What Does it Mean…

    What Does it Mean...

  14. Slide 14: Creo Growth – existing products

    1. US surgical procedure volumes 2010, 4. Winawer SJ, Fletcher RH, Miller L, Millennium Research, RPUS43SV10, Godlee F, Stolar MH, Mulrow CD, et February 2010 al. Colorectal cancer screening: Creo Growth – existing products clinical guidelines and 2. Gastrointest Endosc 2014; 80-133-43 rationale. Ga

  15. Slide 15: Sales Funnel

    Sales Funnel Opportunity Funnel – 339 – all qualified – c100% growth since start of 2022 Attendees Dr Mumtaz Hayat UK Dr. Nisha Patel UK Mr Joseph UK Sebastian Dr Vanja Giljaca UK Dr Neo Seabi South Africa International Pioneer Event Gloria Fernández March 2022 Spain Esparrach Álvaro Terán • 12 Doct

  16. Slide 16: Creo Core Technology

    Creo Core Technology Flexible microwave ablation device Designed for soft tissue ablation where flexibility and small diameter is required Tissue microwave ablation devices for ablation of tumours in a wide range of tissue types – and the smallest . microwave ablation device we know of* Surgical dev

  17. Slide 17: Treating more patients, driving Growth

    Treating more patients, driving Growth Revenue Trend Core Creo Only Advanced Energy Complimentary Devices Expanded Advanced •Strengthen Portfolio •Bundle AE devices with Energy Portfolio •Drive Utilization additional procedural •High-volume devices •Clinical and Economic devices •New Applications Da

  18. Slide 18: Training

    Training

  19. Slide 19: Pioneer Programme

    PIONEER CLINICAL EDUCATION PROGRAMME *

  20. Slide 20: Growth of the Pioneer Programme

    Growth of the Pioneer Programme With a pipeline of experts wanting to be part of the Creo Journey we have significantly increased our training capacity post-pandemic. 2022 has seen: • 200% increase in trainers vs 2021 Global experts providing training all over the world • 350% increase in ex-vivo ac

  21. Slide 21: Health Care Professionals

    Health Care Professionals

  22. Slide 22: KOL View – Dr Blair Jobe

    KOL View – Dr Blair Jobe Dr. Blair Jobe, Director of the Esophageal and Lung Institute and member of the American Board of Surgery and American Foregut Society. Nationally renowned pioneer in the field of minimally invasive surgery and endoscopic therapy for the treatment of esophageal cancer, Barre

  23. Slide 23: Israel

    Israel Quick take up Immediate cases New procedures September 2021 ▪ Identify regional distributor, Tradis Gat, and agree bespoke distribution model for Israel. By May 2022 ▪ 2 doctors identified, trained and performing their first SSD cases. By July 2022 ▪ 8 doctors and counting from hospitals acro

  24. Slide 24: Validating Clinical and Economic Outcomes

    Validating Clinical and Economic Outcomes

  25. Slide 25: Validating Clinical and Economic Outcomes

    Validating Clinical and Economic Outcomes • Registries: • 2 active registries currently with a focus on SSD (both lower GI and Upper GI) and POEM, • Yielding valuable data on safety, efficacy, and shortened learning curve. • Publications: • 2 papers encompassing 300+ procedures from ESD physician, a

  26. Slide 26: Clinical Case Studies

    Clinical Case Studies

  27. Slide 27: Clinical Case Study - India

    Clinical Case Study - India “ The use of this multi-functional Speedboat Submucosal Dissection device has many advantages (SSD) for G-POEM including precise delivery of energy minimising collateral Dr. Mohan Ramchandani | Director of Interventional Endoscopy, AIG injury, and the reduction Hospitals,

  28. Slide 28: Clinical Case Study - USA

    Clinical Case Study - USA “ Use of the Speedboat Inject Speedboat Submucosal Dissection (SSD) Using devices singlehandedly allowed safe and efficient curative Advanced Energy for a LST- mixed lesion in the resection of a large rectal lesion rectum extending to the dentate line that extended to the d

  29. Slide 29: Clinical Case Study - UK

    Clinical Case Study - UK “ SSD is an efficient technique for Speedboat Submucosal Dissection (SSD) Using safe en-bloc resection of advanced polyps of the Advanced Energy on a Mid-Rectal Lateral colorectum. Alternatives for this Spreading Tumour with Focal Depression lesion would be piecemeal EMR tha

  30. Slide 30: Powered by Kamaptive Technology

    N Powered by ~ «* kamaptive > ~N DK tech nology" A

  31. Slide 31: Kamaptive – Creo's Proprietary Intelligent Energy Platform

    Kamaptive™ – Creo’s Proprietary Intelligent Energy Platform Intelligent energy with safety at heart. • Energy with finesse and intelligence • Eliminate collateral damage • Heightened controlled accuracy • Intuitive adaptive interface What is Kamaptive Technology? Kamaptive is Creo Medical’s propriet

  32. Slide 32: Significant Single Use Market Opportunity

    Significant Single Use Market Opportunity (Procedures, 000s) Est. Est. $25bn 2400 $19bn $33bn ablation 2200 2000 market market market 1800 (2017) (2030) (2025) 1600 1400 1200 c.49 million 1000 800 600 Open + Lap + Robotic 400 200 procedures globally 0 growing to c.67 million in 2030 Source: Intuitiv

  33. Slide 33: Robotics Partner Opportunity

    Robotics Partner Opportunity “Robotics is happening right now. When somebody cracks the advanced energy dilemma that still exists for all systems, then there will be no stopping it’s expansion.” Professor Jared Torkington, Colorectal Surgeon, Professor of Surgical Innovation, Cardiff and Vale Health

  34. Slide 34: Collaboration Agreement with Intuitive

    Collaboration Agreement with Intuitive Creo technology to be adapted for use with robotic-assisted surgical platform • Multi-year collaboration agreement with Intuitive – a global technology leader in minimally invasive care and the pioneer of robotic- assisted surgery. • Agreement will see optimisa

  35. Slide 35: Kamaptive Opportunity

    Kamaptive Opportunity • All Kamaptive opportunities planned to be funded development programme • R&D on current devices complete • Creo will be paid to develop new ones…or • Paid to iterate future devices • All aim to be cash positive out of gates – strong margin and/or future royalty streams • Init

  36. Slide 36: Summary

    Summary 36

  37. Slide 37: Two Specific Areas of Focus

    Two Specific Areas of Focus IPO only had Core Creo products, however business has evolved into two Core Markets 1. Core Creo Products and Devices • Three specific areas • USA • EMEA • APAC Core Creo Robotics • R&D completed on product range • Sales and clinical team in place Advances in single-port

  38. Slide 38: Executing the global strategy - 2023

    Executing the global strategy - 2023 2023 and Beyond – Building on Regular Users and delivering Kamaptive Opportunity • Operate EMEA, US and APAC core business from solid foundation with no increase in the cost base • Targeting 80% of revenue from Creo Manufactured Products • EMEA profitable within

  39. Slide 39: Break even and Beyond

    Break even and Beyond Break even – Q4-24 EMEA profitable within FY23 USA target to achieve profitability in short / medium term APAC – slower out of pandemic, profitability in reach off low cost base Revenue growth from Creo Core plus Kamaptive license deals Current signed deal drives team of 10-12

  40. Slide 40: Anything is Possible with the Right Approach

    Anything is Possible with the Right Approach

  41. Slide 41: Slide 41

Creo Medical Group — Investor Presentation (2022) on 6ix